Skip to content
lifestyle.inspiredn.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Protagonist Therapeutics
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
April 28, 2026
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
March 18, 2026
←
Previous Page
1
2